Cat. No. | Product name | CAS No. |
DC66751 |
Glenzocimab
Featured
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. |
2101829-58-5 |
DC66752 | KRN330 Featured | |
DC66753 | Minomic patent anti-Glypican 1 Featured | |
DC66754 | Nih Patent Anti-Glypican-2 Featured | |
DC66755 |
Codrituzumab
Featured
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. |
1365267-33-9 |
DC66756 |
Glembatumumab
Featured
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity. |
1020264-78-1 |
DC66757 | DS-6157 Featured | |
DC66758 | KHK patent anti-CRTH2 Featured | |
DC66759 | BNC101 Featured | |
DC66760 | Multiple seq-one in animal Featured | |
DC66761 |
Talquetamab
Featured
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity. |
2226212-40-2 |
DC66762 | Regeneron patent anti-GREM1 Featured | |
DC66763 | UCB patent anti-Gremlin-1 Featured | |
DC66764 |
Indusatumab
Featured
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody. |
1497400-26-6 |
DC66765 | KHK patent anti-Haptoglobin Featured | |
DC66766 | U3-1565 Featured | |
DC66767 | KHK2866 Featured | |
DC66768 |
Tuvirumab
Featured
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research. |
138660-97-6 |
DC66769 | LY2787106 Featured | |
DC66770 | Ludwig-Maximilians U. anti_Hepsin Featured | |
DC66771 | TAK-701 Featured | |
DC66772 |
Rilotumumab
Featured
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. |
872514-65-3 |